teclistamab, talquetamab, and elranatamab: response rates and data - blood cancer onctalk 2023
Published 5 months ago • 115 plays • Length 5:48Download video MP4
Download video MP3
Similar videos
-
6:03
teclistamab, talquetamab, and elranatamab: response rates and data
-
3:53
the future of bispecific antibodies - blood cancer onctalk 2023
-
2:28:27
vod 2023 blood cancer onctalk
-
1:56
types of bispecific antibodies - blood cancer onctalk 2023
-
3:49
q&a: how do oncologists determine treatment orders? - blood cancer onctalk 2023
-
4:11
treatment options for newly diagnosed aml: venetoclax and midostaurin - blood cancer onctalk
-
6:06
bispecific antibody treatment in non-hodgkin lymphoma: epcoritamab - blood cancers onctalk 2023
-
1:31
are there any ongoing trials for acute leukemia in adults? - blood cancer onctalk
-
2:52
bispecific antibody treatment in non-hodgkin lymphoma: glofitamab - blood cancers onctalk 2023
-
7:39
car t-cell versus bispecific therapies: how oncologists determine treatment - blood cancer onctalk
-
2:47
efficacy of epcoritamab and glofitamab in diffuse large b-cell lymphoma - blood cancers onctalk 2023
-
3:12
what are the pros and cons of car t-cell therapy vs. bispecific antibodies? - blood cancer onctalk
-
5:52
treatment options for al amyloidosis: venetoclax and teclistimab - blood cancer video library 2023
-
6:48
lab tests in multiple myeloma - blood cancer onctalk
-
3:21
bispecific antibodies: amivantamab - onctalk lung 2023
-
6:59
teclistamab in combination with sub-q daratumumab and lenalidomide in myeloma pts: majestec-2
-
58:00
know your myeloma immunotherapy: teclistamab and other bispecifics